The precision of immunological characterization of leukemias was improved by a certain number of technical innovations, particularly hybridoma production and standardization, resulting in monoclonal antibodies and definition of recognised cellular antigens (designated by CD: Cluster of Differentiation).
Introduction
At present, characterization and classification of leukemias in the laboratory is carried out on the basis of morphology, cytochemistry, cytogenetics and immunophenotype analysis. The immunological approach was improved by some technical innovations, particularly hybridoma production and standardization, giving rise to monoclonal antibodies, and by the definition of "Clusters of Differentiation" (CD). Application of these reagents became easier following improvement in flow cytometric methods, production of new fluorochromes and the development of labelling techniques applied to cell suspensions and directed to either surface or cytoplasmic molecules.
The assignment of acute leukemias to a given lineage is an important step for determining prognosis and therapy. Several classifications have been proposed, particularly that of the French Groupe d'Etude Immunologique des Leucémies (GEIL) that proposes an immunologic classification of acute leukemias, based on a scoring system where individual markers are assigned major, intermediate and minor weights on a scale of 1.5, 1 and 0.5 points, respectively. Assignment to a given lineage requires a score of at least 2 with the appropriate marker set. Thus, four categories can be defined, "nul", "pure", "variant" and "multiphenotypic" depending on score combinations in the three lineages B, T and myeloid [5] .
Material and methods
The aim of this work was to determine the immunophenotypic profile of leukemic patients coming from the Sahel region of Tunisia (North Africa). 66 patients were studied aged from 3 days to 71 years (with a mean of 19.6 years). All had a recent diagnosis of leukemia at Farhat Hospital of Sousse.
Immunophenotyping analyses were performed at the Cellular Immunology Laboratory of the National Center of Blood Transfusion of Tunisia. We used a panel of 29 monoclonal antibodies (see below), a direct immunofluorescence reaction on fresh peripheral blood cells with a red cell lysing method (FACSlysing solution of Becton Dickinson) according to Lees et al. [11] and acquisition on a FACSCalibur flow cytometer (Becton Dickinson) with CellQuest software. Data were expressed as percentages of labelled blast cells; positivity thresholds were 30% for B-lineage markers, 90% for T-lineage markers, 20% for myeloid antigens and 7% for immaturity markers (CD34, CD117, CD1a and CD10).
Monoclonal antibodies used (Immunotech):
FITC) -CD16 (FITC or PE) -CD19 (FITC or PE) -CD20 (FITC or PE) -CD22 (FITC) -CD23 (FITC) -CD33 (PE) -CD34 (FITC or PE) -CD36 (FITC) -CD38 (FITC) -CD41 (FITC) -CD45 (FITC) -CD56 (PE) -CD65 (FITC) -CD71 (FITC) -CD117 (PE) -HLA DR (FITC) -FMC7 (FITC) -Isotypic controles (Mouse antibodies:
IgG1 FITC, IgG1 PE, IgG2a FITC, IgM FITC)
Results and discussion
Among the 66 samples studied, 62 could be assigned to a given lineage (Table 1) ; that means that we were able to type an acute leukemia in a simple blood sample, in 93.9% of cases. The 4 cases for whom immunophenotyping was apparently normal, were patients who had received intensive corticosteroid therapy during the last few days preceding their blood collection.
Among the 62 acute leukemias newly diagnosed and sent to our laboratory, we found 21 B-ALL (33.9%), 12 T-ALL (19.4%) 27 AML (43.5%) and 2 biphenotypic acute leukemias (3.23%).
Considering the distribution according to age, 39 cases (62.9%) were young persons (from 0 to 20 yrs), whereas only 23 cases (37.1%) were adults (aged 21 or over). This could be explained, in part, by the fact that nearly 2/3 of the Tunisian population are under 30.
Furthermore (Table 2 ) and in accordance with the literature [10] , 71.4% of B-ALL and 58.3% of T-ALL were children under 10, whereas that age bracket contains only 14.8% of AML; in fact, the majority of AML (63%) are adults over 21.
Moreover (Table 3) , within the 0-10 yr age bracket, B-ALL are in the majority (57.7%), when compared with AML (15.4%); examining successively older age cohorts the B-ALL proportion decreases (8.7% for those over 21) whereas AML increases (73.9% for those over 21); these observations agree well with the literature [8] .
Finally (Table1 ), among the 27 AML cases investigated, 12 (44.4%) coexpress markers of other lineages: 22.2% (6 cases) coexpress the CD56 marker, which is relatively high in comparison to previous reports (5.71% according to Scott, 1994 ); 14.8% (4 cases) coexpress CD19 (one of which coexpress CD56) and one case (3.7%) coexpresses the CD2 marker. Coexpression of CD19 is correlated with AML2 with t (8,21) translocation [9] and according to the CALGB study, CD56 coexpression carries a bad prognosis [1, 4] . In non-AML cases, we detected just one instance of coexpression. This was a case of CD13 positiveT-ALL (8.33% of T-ALL). 
Conclusion
Over the past twenty years, blast immunophenotyping have become very important in acute leukemia diagnosis. Classification by cytology alone, or even coupled with cytochemistry, can be problematic. This study shows that immunophenotyping by flow cytometry, which has recently become available in Tunisia, permits the assignment of the leukaemic cells present in a given sample to a precise cellular lineage. More interesting is the fact that we could, in a great number of cases, avoid taking a bone marrow sample which could be traumatic for the patient. However, blast immunophenotyping cannot replace cytology; it simply constitutes a valuable complement in the precise diagnostic of acute leukemia and lymphoma.
